Amgen Inc (Amgen) focuses on discovering, developing, manufacturing, and delivering products to treat serious diseases such as cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Amgen focuses its R&D on novel human therapeutics for the treatment of serious illnesses, leveraging strengths in human genetics, novel biology, and protein engineering. The company aims to choose the optimal modality for drug targets and diseases, using cutting-edge science and technology to study biological mechanisms for developing therapies. Amgen’s discovery research programs may yield targets leading to the development of human therapeutics delivered as large molecules, small molecules, or new modalities. The company increasingly focuses on human genetics to enhance the likelihood of success and has major R&D centers in the US, Iceland, and the UK. Amgen is focused on advancing science and innovation by utilizing tools like AI, generative biology, and human data to discover unknowns and develop precision medicines for serious illnesses. The company emphasizes human genetics, novel biology, and protein engineering to create novel human therapeutics. It leverages biologic expertise to select optimal modalities for drug targets and diseases, aiming to improve patient outcomes through cutting-edge science and technology. The company aims to enhance its R&D capabilities, product pipeline, and marketed product base through internal efforts and strategic acquisitions or partnerships. Additionally, the company has commenced construction on a cutting-edge research and development facility in Thousand Oaks, California, in 2025 to enhance collaboration and innovation across R&D and process development activities. In FY2025, the company spent US$7,272 million on its R&D activities, which as a percentage of revenue, which stood at 19.8%, and grew 21.9% YoY. A few of its pipeline products in Phase III include AIMOVIG to treat Pediatric Migraine; AMJEVITA to treat Inflammation; bemarituzumab to treat gastric and gastroesophageal junction cancers; blincyto to treat acute lymphoblastic leukemia; dazodalibep to treat sjogren’s disease; imdelltra to treat small cell lung cancer; kyprolis to treat multiple myeloma; lumakras to treat advanced colorectal cancer; nplate to treat chemotherapy-induced thrombocytopenia; parsabiv to treat pediatric secondary hyperparathyroidism; pavblu to treat investigational biosimilar; prolia to treat pediatric glucocorticoid-induced osteoporosis; repatha to treat hypercholesterolemia; tavneos to treat pediatric anti-neutrophil cytoplasmic autoantibody-associated vasculitis; tepezza to treat thyroid eye disease; and xaluritamig to treat prostate cancer; among others.